Get the Stockscreener App
2.3705
0.00%
0.0095
Phio Pharmaceuticals Corp stock is traded at $2.3705, with a volume of 1,792.
It is up +0.00% in the last 24 hours and down -25.16% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.38
Open:
$2.38
24h Volume:
1,792
Relative Volume:
0.03
Market Cap:
$2.09M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2334
EPS:
-10.156
Net Cash Flow:
$-11.09M
1W Performance:
+6.73%
1M Performance:
-25.16%
6M Performance:
-65.20%
1Y Performance:
-72.97%
1-Day Range:
$2.3601
$2.38
1-Week Range:
$2.1678
$2.66
52-Week Range:
$2.1678
$18.81
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PHIO | 2.3601 | 2.09M | 0 | -11.66M | -11.09M | -10.16 |
| VRTX | 447.24 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.54 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.49 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.58 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.63 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals Announces Completion of Enrollment in Second - The Kingston Whig-Standard
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study - Newsfile
Phio Pharmaceuticals Corp. (PHIO) Quarterly 10-Q Report - Quartz
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Alberta Daily Herald Tribune
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PHIO stock touches 52-week low at $2.38 amid market challenges - Investing.com
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
PHIOPhio Pharmaceuticals Corp. Latest Stock News & Market Updates - StockTitan
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Quantisnow
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th - Shoreline Beacon
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Nasdaq Financial 100 Index (IXF) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - StockTitan
Phio Pharmaceuticals presents novel cancer therapy data - Investing.com
Phio Pharmaceuticals presents novel cancer therapy data By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference - Newsfile
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - Knox Daily
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA - MSN
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells - Newsfile
Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 2.5% – Time to Sell? - Defense World
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference - Yahoo Finance
Nu Holdings Ltd Cl A (NU-N) QuotePress Release - The Globe and Mail
This trade activity should not be overlooked: Hyliion Holdings Corporation (HYLN) - SETE News
INTASYL Technology and Compounds to be Focus of Presentation at 20th - North Bay Nugget
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society - Newsfile
HITE Hedge Asset Management LLC Sells 12,931 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Hyliion Holdings Corporation (HYLN) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Financial Metrics Unveiled: P3 Health Partners Inc (PIII)’s Key Ratios in the Spotlight - The Dwinnex
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World
King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World
Texas Permanent School Fund Corp Has $1.39 Million Stock Holdings in PHINIA Inc. (NYSE:PHIN) - Defense World
Thailand's new celebrity baby pygmy hippo, Moo Deng - The Business Standard
Bokf Na Has $58,000 Stock Position in Haleon plc (NYSE:HLN) - Defense World
American Century Companies Inc. Raises Position in PHINIA Inc. (NYSE:PHIN) - Defense World
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):